RGMA Binding Protein and Use Thereof - Tanabe Pharma, EP3584260A1
Summary
The European Patent Office published patent application EP3584260A1 on April 15, 2026, covering RGMA (Glass-like Rolling Membrane Protein A) binding proteins and their therapeutic uses. The patent names Tanabe Pharma Corporation, Osaka University, and National University Corporation Chiba University as applicants, with inventors HASHIMOTO Motonori and YAMASHITA Toshihide. The invention is classified under A61P 25/00 (nervous system diseases) and A61P 37/02 (immunological disorders), covering therapeutic applications in neurological and immunological disease treatment.
“Tanabe Pharma Corporation, Osaka University, National University Corporation Chiba University”
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 36 changes logged to date.
What changed
The European Patent Office granted patent EP3584260A1 for RGMA (Glass-like Rolling Membrane Protein A) binding proteins and methods of use. This is a published European patent application designating 38 member states including all major European markets. The patent covers therapeutic applications including neurological conditions (A61P 25/00) and immunological disorders (A61P 37/02).
For Tanabe Pharma Corporation and its university research partners, this patent publication establishes intellectual property protection across European markets for their RGMA binding protein technology. Competitors developing similar membrane protein binding therapeutics should review the patent claims for potential freedom-to-operate issues. The patent's broad coverage across multiple therapeutic classifications suggests potential applications beyond its initial filing scope.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RGMA BINDING PROTEIN AND USE THEREOF
Publication EP3584260A1 Kind: A1 Apr 15, 2026
Applicants
Tanabe Pharma Corporation, Osaka University, National University Corporation Chiba University
Inventors
HASHIMOTO, Motonori, YAMASHITA, Toshihide
IPC Classifications
C07K 16/28 20060101AFI20191121BHEP A61K 39/395 20060101ALI20191121BHEP A61P 25/00 20060101ALI20191121BHEP A61P 37/02 20060101ALI20191121BHEP C07K 16/46 20060101ALI20191121BHEP C12N 1/15 20060101ALI20191121BHEP C12N 1/19 20060101ALI20191121BHEP C12N 1/21 20060101ALI20191121BHEP C12N 5/10 20060101ALI20191121BHEP C12N 15/09 20060101ALI20191121BHEP C12P 21/08 20060101ALI20191121BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.